Cue Biopharma Presents at The Promise of Interleukin-2 Therapy Conference Page 1

BOSTON, Sept. 3, 2024 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of therapeutic biologics to selectively target and modulate disease-specific T cells, today announced that members of its management team will give two presentations at The Promise of Interleukin-2 Therapy conference, taking place September 4-7, 2024 in Paris, France.

Presentation details
Date and Time: Friday, September 6, 2024, 4:00 PM CET
Presentation title: CUE-401: A novel IL-2/TGF-beta fusion protein for the induction and expansion of FOXP3+ regulatory T cells
Presenter: Steven Quayle, Ph.D., Vice President and Chief, Biological Research and Translational Medicine, Cue Biopharma